Stephen Strittmatter on a first-in-human trial for treating

Stephen Strittmatter on a first-in-human trial for treating chronic cervical spinal cord injury

Listen now

Description

Stephen Strittmatter (Yale School of Medicine, CT, USA) discusses his first-in-human and randomised trial of a soluble Nogo-receptor-Fc decoy in patients with chronic cervical spinal cord injury. The Article is published in the August issue of The Lancet Neurology. Read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00215-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_laneur Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

More Episodes

See all »

Suvankar Pal on the motor neuron disease trial MND-SMART

Professor Suvankar Pal (University of Edinburgh) joins Sarah Passey (Senior Editor at The Lancet Neurology) to discuss the first findings from the MND-SMART trial of treatments for motor neuron disease. The Article is published in the November issue of The Lancet Neurology.Continue this...

Published 10/16/24

The Lancet Neurology in conversation with

Published 10/16/24

Jorge Correale and Lilyana Amezcua on differential diagnosis of multiple sclerosis

Prof Jorge Correale and Dr Lilyana Amezcua talk to The Lancet Neurology about their Personal View papers, published in the October 2024 issue, on the differential diagnosis of multiple sclerosis in regions outside North America and Western Europe and in people from minority ethnic or racial...

Published 09/18/24